Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination

Cancer. 1994 Mar 1;73(5):1398-405. doi: 10.1002/1097-0142(19940301)73:5<1398::aid-cncr2820730514>3.0.co;2-9.

Abstract

Background: Evidence suggests that plasminogen activators and their inhibitors play an important role in tumor spread.

Methods: In this study, we measured the antigen levels of urokinase (u-PA), tissue plasminogen activator (t-PA), type 1 plasminogen activator inhibitor (PAI-1), and type 2 plasminogen activator inhibitor (PAI-2), and cancer tissue (19 adenocarcinomas and 19 squamous cell carcinomas) and normal lung tissue.

Results: u-PA, PAI-1, and PAI-2 antigen levels in cancer tissue were significantly higher than those in normal tissue (P < 0.001 in u-PA and PAI-1; P < 0.005 in PAI-2), whereas t-PA antigen levels in cancer tissue were significantly lower than those in normal tissue (P < 0.005). In case with lymph node involvement (LN+ cases), PAI-2 antigen levels were significantly lower than those in cases without lymph node involvement (LN- cases) (P < 0.02), whereas there was no difference in either u-PA or PAI-1 antigen levels between these two groups. Furthermore, u-PA antigen levels showed a significant positive correlation with PAI-2 antigen levels in LN- cases (r = 0.696; P < 0.005), although there was no correlation between these two parameters in LN+ cases.

Conclusions: The antigen levels of u-PA, PAI-1, and PAI-2 in cancer tissue were significantly higher than those in normal tissue, and lower content of PAI-2 was associated with lymph node metastasis.

MeSH terms

  • Adenocarcinoma / chemistry
  • Adult
  • Aged
  • Aged, 80 and over
  • Antigens / analysis
  • Carcinoma, Non-Small-Cell Lung / chemistry*
  • Carcinoma, Squamous Cell / chemistry
  • Female
  • Humans
  • Immunohistochemistry
  • Lung Neoplasms / chemistry*
  • Lymphatic Metastasis / diagnosis*
  • Male
  • Middle Aged
  • Plasminogen Activator Inhibitor 1 / analysis*
  • Plasminogen Activator Inhibitor 2 / analysis*
  • Tissue Plasminogen Activator / analysis*
  • Urokinase-Type Plasminogen Activator / analysis*

Substances

  • Antigens
  • Plasminogen Activator Inhibitor 1
  • Plasminogen Activator Inhibitor 2
  • Tissue Plasminogen Activator
  • Urokinase-Type Plasminogen Activator